Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT

Inclusion Criteria: * Patients with haematological malignancies such as * any acute myeloid leukemia (AML) beyond Complete Remission (CR) 1 * any acute lymphoblastic leukemia (ALL) beyond CR1 * multiple myeloma (MM) at any relapse/progression, except refractory disease * MM with unfavourable cytogenetic profile at diagnosis * MM with less than a partial response (PR) after induction therapy * Karnofsky Index ≥ 80 % * Adequate contraception in female patients of child-bearing potential. * Written informed consent * Availability of one of the following: * A matched related or unrelated donor (MRD or MUD) Exclusion Criteria: * A hematopoietic cell transplantation-specific comorbidity index \> 4 * Active non-controlled infectious disease at the moment of inclusion * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection * Impaired liver function (Bilirubin \> 2.0 x upper normal limit; Transaminases \> 3.0 x upper normal limit) * Impaired renal function (Creatinine-clearance \< 60 ml/min; Serum Creatinine \> 1.5 x upper normal limit). * Pleural effusion or ascites \> 1.0 L * Pregnancy or lactation * Known hypersensitivity to treosulfan and/or fludarabine and/or rapamycin * Non-co-operative behaviour or non-compliance * Psychiatric diseases or conditions that might impair the ability to give informed consent * Previous spinal cord radiotherapy with dose ≥ 45 Gy equivalent